Genentech/Roche announced updated data from a pivotal Phase III CLL14 study that highlights Venclexta (venetoclax) plus Gazyva (obinutuzumab) combination treatment...
Genentech/Roche Group announced that the Phase III MURANO study, which evaluated Venclexta (venetoclax) in combination with Rituxan (rituximab) in people...
The FDA has approved Venclexta (venetoclax), from AbbVie, for the treatment of patients with chronic lymphocytic leukemia (CLL) who have...
Genentech/Roche announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta...
The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...
Genentech/Roche announced updated data from a pivotal Phase III MURANO study that highlights the impact of Venclexta (venetoclax) plus Rituxan...
Genentech, a member of the Roche Group announced positive results from the Phase III VIALE-A study, evaluating Venclexta (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy.
Genentech/Roche announced that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in...
Roche announced that the FDA has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with...
Results from the Phase III Murano trial of Venclexta (venetoclax) from AbbVie, and Rituxan (rituximab), from Roche/Genentech, significantly improved progression-free...